[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a0e2fae7f8aff859095c5cf1a1a2261d9b357f5b66213b8dfc4c49ac5a9ac066",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734539580,
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "id": 132064403,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a0e2fae7f8aff859095c5cf1a1a2261d9b357f5b66213b8dfc4c49ac5a9ac066"
    }
  },
  {
    "ts": null,
    "headline": "Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.",
    "summary": "The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss market.",
    "url": "https://finnhub.io/api/news?id=d9f76ba284d8441ddf69772ab7bf1f4b6e667b52e96ca4a7d3c32fc823ed3c2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734535500,
      "headline": "Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.",
      "id": 132040275,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss market.",
      "url": "https://finnhub.io/api/news?id=d9f76ba284d8441ddf69772ab7bf1f4b6e667b52e96ca4a7d3c32fc823ed3c2e"
    }
  },
  {
    "ts": null,
    "headline": "FDA targets more online vendors selling unapproved GLP-1RA products",
    "summary": "Improper advertising on media constituted a large part of traffic directed to the companies’ websites.",
    "url": "https://finnhub.io/api/news?id=e491a3bea9063ee53cb836abbbdc0350405129b4b2356daad62de862bcc9227e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734525368,
      "headline": "FDA targets more online vendors selling unapproved GLP-1RA products",
      "id": 132039120,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_2520433547.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Improper advertising on media constituted a large part of traffic directed to the companies’ websites.",
      "url": "https://finnhub.io/api/news?id=e491a3bea9063ee53cb836abbbdc0350405129b4b2356daad62de862bcc9227e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call",
    "summary": "Pfizerâs financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a \"Buy\" as we look toward 2025.",
    "url": "https://finnhub.io/api/news?id=8f79def61af3be1708e5b903db4bf9729d73b4b340f50bbbac83940c1eaa95c5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734521024,
      "headline": "Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call",
      "id": 132039689,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178153244/image_2178153244.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Pfizerâs financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a \"Buy\" as we look toward 2025.",
      "url": "https://finnhub.io/api/news?id=8f79def61af3be1708e5b903db4bf9729d73b4b340f50bbbac83940c1eaa95c5"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug",
    "summary": "When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind.  Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it has been highly effective in doing that.  The success of Ozempic and Wegovy has helped the company behind the products, Novo Nordisk (NYSE: NVO), become one of the most valuable healthcare stocks in the world.",
    "url": "https://finnhub.io/api/news?id=65e10557526be0928f39902bbd872ace0bf1683efb11236cabc87d426e04d1cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734520500,
      "headline": "Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug",
      "id": 132039121,
      "image": "https://g.foolcdn.com/editorial/images/801006/a-physician-using-a-scale-to-measure-a-persons-weight.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind.  Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it has been highly effective in doing that.  The success of Ozempic and Wegovy has helped the company behind the products, Novo Nordisk (NYSE: NVO), become one of the most valuable healthcare stocks in the world.",
      "url": "https://finnhub.io/api/news?id=65e10557526be0928f39902bbd872ace0bf1683efb11236cabc87d426e04d1cb"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout",
    "summary": "What Eli Lilly (NYSE: LLY) is doing is far more impressive.  While many investors may buy it for its growth potential, here's why it can also make for an exceptional dividend stock to buy and hold.  On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase.",
    "url": "https://finnhub.io/api/news?id=cfd247ae59416e25501994cec890eb725e4a3f92f7f47a13b41e6f9ceebf81ec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734516660,
      "headline": "Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout",
      "id": 132039122,
      "image": "https://g.foolcdn.com/editorial/images/801008/an-excited-couple-looking-at-a-cell-phone.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "What Eli Lilly (NYSE: LLY) is doing is far more impressive.  While many investors may buy it for its growth potential, here's why it can also make for an exceptional dividend stock to buy and hold.  On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase.",
      "url": "https://finnhub.io/api/news?id=cfd247ae59416e25501994cec890eb725e4a3f92f7f47a13b41e6f9ceebf81ec"
    }
  },
  {
    "ts": null,
    "headline": "Egyptian Drug Authority approves Lilly and EVA’s insulin injection",
    "summary": "Lilly has been instrumental in supplying its API for insulin at a low cost and offering technology transfer to EVA.",
    "url": "https://finnhub.io/api/news?id=28cc6703691e830a69f5dbcd6d3adecc2403c120c170452b66f0a00bfb9f9446",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734514706,
      "headline": "Egyptian Drug Authority approves Lilly and EVA’s insulin injection",
      "id": 132039123,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Pharma-1-LillyEva.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly has been instrumental in supplying its API for insulin at a low cost and offering technology transfer to EVA.",
      "url": "https://finnhub.io/api/news?id=28cc6703691e830a69f5dbcd6d3adecc2403c120c170452b66f0a00bfb9f9446"
    }
  },
  {
    "ts": null,
    "headline": "The Gabelli Global Rising Income & Dividend Fund Q3 2024 Commentary",
    "summary": "The Gabelli Global Rising Income & Dividend Fund (class I) returned 8.35% for the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=e3f1b5ad7d89f1d0e3c6c4f1a86c02fcf8089d4d3089f766d33978b60c33e64e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734514500,
      "headline": "The Gabelli Global Rising Income & Dividend Fund Q3 2024 Commentary",
      "id": 132039071,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417583870/image_1417583870.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Gabelli Global Rising Income & Dividend Fund (class I) returned 8.35% for the third quarter of 2024. Click here to read the full commentary. \n",
      "url": "https://finnhub.io/api/news?id=e3f1b5ad7d89f1d0e3c6c4f1a86c02fcf8089d4d3089f766d33978b60c33e64e"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma’s new DTC play: partnering with digital health providers",
    "summary": "The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.",
    "url": "https://finnhub.io/api/news?id=b040070ac9cd5ed610783d773743a0ec5fa1dfb8cca2a202d7124160fec4e76d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734507560,
      "headline": "Big Pharma’s new DTC play: partnering with digital health providers",
      "id": 132039124,
      "image": "https://imgproxy.divecdn.com/7RQWbb4vOgXkLincF6pxOGRRVc-yrwvglzJqowSC1zE/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDgxMzQwX3kzQ1NFUFguanBn.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.",
      "url": "https://finnhub.io/api/news?id=b040070ac9cd5ed610783d773743a0ec5fa1dfb8cca2a202d7124160fec4e76d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: China approves Alzheimer's treatment",
    "summary": "Eli Lilly has announced that the National Medical Products Administration in China has approved Kisunla for adults with early symptomatic Alzheimer's disease.This includes people with mild cognitive...",
    "url": "https://finnhub.io/api/news?id=9477b8c08775be394ddfb1d172047db4dd98a9ed9b5e5171414f38a9148c7f89",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734493388,
      "headline": "Eli Lilly: China approves Alzheimer's treatment",
      "id": 132037093,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has announced that the National Medical Products Administration in China has approved Kisunla for adults with early symptomatic Alzheimer's disease.This includes people with mild cognitive...",
      "url": "https://finnhub.io/api/news?id=9477b8c08775be394ddfb1d172047db4dd98a9ed9b5e5171414f38a9148c7f89"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Alzheimer's treatment approved in China",
    "summary": "China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the United States, Japan and the UK, Lilly said in a statement.  It also caused brain swelling in nearly a quarter of patients and brain bleeding in nearly a third, but most cases were mild.",
    "url": "https://finnhub.io/api/news?id=67bc2f67b374e070fc1134bd712f8d9ef276b627635afc1c00cdc7fd520e6f1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734486633,
      "headline": "Eli Lilly's Alzheimer's treatment approved in China",
      "id": 132033774,
      "image": "https://media.zenfs.com/en/reuters.com/72413e0bd488094a15ef4b0b5a8ec8ef",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the United States, Japan and the UK, Lilly said in a statement.  It also caused brain swelling in nearly a quarter of patients and brain bleeding in nearly a third, but most cases were mild.",
      "url": "https://finnhub.io/api/news?id=67bc2f67b374e070fc1134bd712f8d9ef276b627635afc1c00cdc7fd520e6f1f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly receives approval for Alzheimer's treatment in China",
    "summary": "US pharmaceutical company Eli Lilly announces that the National Medical Products Administration in China has approved the drug Kisunla , according to a press release. Kisunla is a treatment for adults...",
    "url": "https://finnhub.io/api/news?id=89b3527bce367f30d958bebbe9a7c0be560e05e01365d657de850e1b77024928",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734484331,
      "headline": "Eli Lilly receives approval for Alzheimer's treatment in China",
      "id": 132035910,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "US pharmaceutical company Eli Lilly announces that the National Medical Products Administration in China has approved the drug Kisunla , according to a press release. Kisunla is a treatment for adults...",
      "url": "https://finnhub.io/api/news?id=89b3527bce367f30d958bebbe9a7c0be560e05e01365d657de850e1b77024928"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of Alzheimer's disease who have confirmed amyloid pathology.1,2",
    "url": "https://finnhub.io/api/news?id=37ce031e61036e8d9b909e6193e613d633a1ee036e66613b24ab9aaf6f6013af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734483600,
      "headline": "Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease",
      "id": 132033775,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of Alzheimer's disease who have confirmed amyloid pathology.1,2",
      "url": "https://finnhub.io/api/news?id=37ce031e61036e8d9b909e6193e613d633a1ee036e66613b24ab9aaf6f6013af"
    }
  }
]